Launch of Cernilton-A Capsule
Exclusive Treatment for Benign Prostatic Hyperplasia and Chronic Nonbacterial Prostatitis
Expanding Options in the Korean Urological Disease Market
DongKoo Bio & Pharma announced on August 19 that it will launch 'Cernilton-A Capsule', a treatment for benign prostatic hyperplasia and chronic nonbacterial prostatitis, on September 1.
This product contains extracts of rye, great burdock, and corn pollen, and offers anti-inflammatory, antiproliferative, and smooth muscle modulation effects. The main ingredient uses the same formulation as the original 'Cernilton Tablet', developed by the Swedish company Cernelle. DongKoo Bio & Pharma will be the exclusive distributor of Cernilton-A Capsule.
Cernilton-A Capsule can be prescribed at all hospitals and clinics nationwide, including university hospitals, and the company plans to actively promote the product through various academic societies such as the Korean Urological Association, the Korean Prostate Society, the Korean Society for Men’s Health and Aging, and the Korean Urological Association of Private Practitioners.
The company stated that, through this launch, it aims not only to improve voiding symptoms caused by benign prostatic hyperplasia, but also to expand the lower urinary tract symptom treatment market as the only medication in Korea approved for chronic nonbacterial prostatitis. The effect of improving voiding symptoms is even greater when Cernilton-A Capsule is used in combination with tamsulosin.
As of last year, the number of patients with benign prostatic hyperplasia in Korea was about 1.58 million, an increase of approximately 21% compared to 2020. The prevalence rate reaches 30-40% among men over 40. Major treatments include alpha-blockers (such as tamsulosin) and 5-alpha reductase inhibitors (such as dutasteride).
As of last year, there were about 250,000 patients with inflammatory prostate diseases, accounting for 15-20% of urology outpatients. Cernilton-A Capsule demonstrated improvements in total NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) score, pain, and quality of life (QoL) in a domestic multicenter clinical trial involving patients with chronic prostatitis/chronic pelvic pain syndrome whose symptoms persisted for more than three months. It is the only medication in Korea approved for chronic nonbacterial prostatitis.
Chairman Cho Yongjun of DongKoo Bio & Pharma stated, "Cernilton-A Capsule will provide a new treatment option for lower urinary tract symptoms and create synergy with existing therapies," adding, "Along with the upcoming improved combination drugs 'Euroguard' (dutasteride + tadalafil) and 'Eurorin', we aim to establish ourselves as a leader in the urological disease treatment market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
